Data from preclinical studies presented at the AACR in 2022 showed that the drug LY-3537982 had good activity, with inhibiting KRAS-GTP binding in lung cancer cell lines carrying the KARSG12C variant. The gene discussed is KRAS; the disease is lung carcinoma.